BOTHELL, WA--(MARKET WIRE)--Sep 18, 2007 -- Eden Bioscience Corporation (NasdaqCM:EDEN - News) today announced that on September 12, 2007 it received a Nasdaq Staff Deficiency Letter from the Nasdaq Stock Market notifying it that the bid price per share for the Company’s common stock has closed below the $1.00 minimum bid price requirement for 30 consecutive trading days and that, as a result, the Company no longer meets The Nasdaq Capital Market’s minimum bid price requirement for continued listing set forth in Marketplace Rule 4310(c)(4).
